Nanoviricides News

NanoViricides CEO Discusses NV-387's Broad-spectrum Antiviral Potential | NYSE-A:NNVC

Proactive InvestorsMay 13 11:13 ET

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. , a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's

AccesswireMay 10 06:30 ET

NanoViricides to Showcase Lead Drug Asset's Progress at EF Hutton Annual Global Conference | NYSE-A:NNVC

Proactive InvestorsMay 10 04:58 ET

NanoViricides Reports Research With NV-387 Showing Promising Results Against Multiple Viruses | NYSE-A:NNVC

Proactive InvestorsMay 9 08:25 ET

NanoViricides Reports Breakthrough in Treating Airborne Viruses, Boosting Lifespan in Infected Mice

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against or

BenzingaMay 8 06:37 ET

Express News | NanoViricides Inc: NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission

ReutersMay 8 06:34 ET

Express News | NanoViricides Inc: Ultra-Broad Antiviral Activity Spectrum of NV-387 Includes Activity Against Orthopoxvirus Family (Smallpox/Mpox)

ReutersMay 8 06:34 ET

A Novel Broad-Spectrum Antiviral With Activity Against Smallpox/Mpox

Stockhouse May 8 06:30 ET

NanoViricides Says Lead Asset Shows Antiviral Activity Against Smallpox and Mpox | NYSE-A:NNVC

Proactive InvestorsMay 8 05:05 ET

NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers

Seeking AlphaMay 7 10:01 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

BenzingaMay 6 12:31 ET

Express News | NanoViricides Shares Are Trading Higher After the Company Announced Its Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu

BenzingaMay 6 10:27 ET

Express News | NanoViricides Inc: Approved Anti-Influenza Drugs Includes Tamiflu, Rapivab, and Xofluza

ReutersMay 6 06:34 ET

Express News | NanoViricides: Anti-Influenza Activity of NV-387 Given Orally Substantially Superior to All 3 Approved Anti-Influenza Drugs

ReutersMay 6 06:34 ET

Express News | NanoViricides Inc: Ultra-Broad Antiviral Activity Spectrum of NV-387 Includes Influenza a Viruses, Possibly Including Bird Flu H5N1 Virus as Well

ReutersMay 6 06:33 ET

NanoViricides' Broad-Spectrum Antiviral NV-387 Offers Protection Against Influenza A and Bird Flu

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses

moomoo NewsMay 6 06:33 ET

A Novel Broad-Spectrum Antiviral With Activity Against Influenza A

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (the

AccesswireMay 6 06:30 ET

NanoViricides Drug Asset Shows 'superior Antiviral Effects' Against Influenza A | NYSE-A:NNVC

Proactive InvestorsMay 6 05:16 ET

Express News | NanoViricides Reports That The Phase I NV-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon

BenzingaApr 30 06:34 ET

NanoViricides Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of

AccesswireApr 30 06:30 ET